Futura Medical plc announced that its breakthrough, topical gel formulation for the treatment of erectile dysfunction (ED), MED3000, under the brand name Eroxon®, is now available for purchase in the UK. Futura's EU and UK distribution partner, Cooper Consumer Health, a leading International independent self-care organisation, has announced that Eroxon® is now available from boots.com and is being rolled out in store from 18th April 2023. The prevalence of ED disrupts the lives of at least 1 in 5 men globally with around 22 million men suffering ED in the US and 20 million men in the UK, France, Italy, Spain and Germany.

ED is a growing problem, with around half of men over the age of 40 experiencing ED and a quarter of men diagnosed with ED now being under the age of 40. This is being driven by an ageing population, increased obesity and prevalence of health conditions such as diabetes which contribute to erectile problems, as well as societal pressures and "performance anxiety" issues in the case of younger men. There has been little innovation in ED treatments in over a decade and many patients continue to suffer dissatisfaction with existing treatments.

Eroxon®, which is fast-acting with minimal side-effects, has the opportunity to provide an alternative option and significant benefits compared to existing ED treatments, especially for those patients seeking a spontaneous intercourse experience as Eroxon® helps users get an erection within 10 minutes. MED3000 is the first pan-European topical treatment for ED available without the need of a doctor's prescription and available over the counter. MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action.

Futura has previously conducted an initial Phase 3 study using MED3000 in ED, referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021.